The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index; 18 of the 49 sources its claims cite were checked for support.
Diagnosis of mast cell activation syndrome: a global "consensus-2"
Open accessAbstract
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast cell activation syndrome" (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a "consensus" (re-termed here as "consensus-1"). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as "consensus-2"), resembling "consensus-1" in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by "consensus-2" criteria has potential to be problematic, but underdiagnosis by "consensus-1" criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.
Overview
CoChat Summary
TL;DR
The paper reviews two main proposals for diagnosing mast cell activation syndrome (MCAS), termed consensus-1 and consensus-2, and argues that either is valid, reasonable, and helpful until more definitive research is available. It emphasizes that underdiagnosis by restrictive criteria is a larger concern than overdiagnosis, given prevalence estimates up to 17% and frequent treatment response.
Key findings
- Two principal diagnostic proposals exist: consensus-1 (Valent et al., originally 2010/2012, updated 2019) and consensus-2 (Molderings et al., originally 2011, updated 2017); they differ substantially in the number of patients qualifying for diagnosis and thus treatment.
- MCAS prevalence estimates range from “rare” to as high as 17% of the general population; allergy prevalence is cited as 10–50%, and hereditary alpha-tryptasemia (HAT) is estimated at approximately 4–6% of the population.
- Consensus-2 considers a wider range of symptoms and mediators (tryptase, chromogranin A, heparin, PGD2, histamine, N-MH, 11-β-PGF2α, LTE4), while consensus-1 emphasizes a “20% + 2” tryptase rise and requires at least partial response to antihistamines and/or cromolyn; elevated plasma heparin is reported in approximately 80% of patients clinically demonstrating MCA symptoms when measured with a sufficiently sensitive assay.
- HAT appears to fit within the MCAS spectrum, with no prognostic or management differences yet identified; TPSAB1 testing is suggested mainly for investigative settings and for persistent mild tryptase elevation (e.g., ≤20 ng/mL).
Methods
- Literature search as of October 27, 2019: PubMed “mast cell activation syndrome” yielded 138 articles and Google Scholar yielded 1410; nine publications offering new or modified diagnostic schemes were identified and grouped into two principal schools of thought.
- Searches for “hereditary alpha-tryptasemia” and “TPSAB1” yielded 1 and 150 articles on PubMed and 44 and 847 on Google Scholar, respectively; principal papers and selected others were read.
- The analysis assessed each diagnostic school for validity of diagnostic criteria, diagnostic accuracy, and practicality; no primary data collection or new patient study was performed.
Limitations
- Stated: no study has yet compared the validity of any one MCAS diagnostic criteria proposal against any other, and no large-scale studies of MCAS aspects exist; the two proposals produce incomparable patient populations for research.
- Stated: MCAS is extraordinarily complex and heterogeneous, routine somatic mutational profiling in mast cells is unavailable, and the HAT definition is challenged by findings that about 8% of patients with redundant TPSAB1 have no tryptase elevation.
- Evident: this is a consensus/opinion review authored largely by proponents of consensus-2, not an empirical validation study, so its recommendations reflect that perspective.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
11 Valid · 9 Not valid · 12 Not checked · 40 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“increasing appreciation that MCAS is prevalent (up to 17% of the general population)”
What the sources say
- Partly supportedcites [11] Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. PLoS One 2013;8:e76241. sourceExperimental — accuracy not yet measured
The Discussion reports approximately 17% *suspected MCAD* in a German general-population control group and says this is probably due to the common MCAS subtype. It does not establish 17% as an MCAS-specific prevalence estimate; the Discussion also cautions that self-report and response bias may have inflated the MCAD estimate. (LLM, conf=0.86)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement”
- Also stated in: § Introduction · hedged
“experience to date (e.g.[12]) suggesting that most MCAS patients, regardless of the (typically decades long) duration of their complex multisystem unwellness prior to diagnosis, eventually identify some regimen which helps them gain significant, largely sustainable improvement”
What the sources say
- Partly supportedcites [12] Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci 2017;353:207–15. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the authors’ experience, most patients eventually find regimens that make them feel significantly better than their pre-treatment baseline the majority of the time. The Results report long and varied delays before diagnosis, but the paper does not establish that treatment improvement occurs regardless of illness duration; the claim also presents an experiential observation more definitively than the source does. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Two principal proposals for diagnostic criteria have emerged.”
- Also stated in: § Introduction · plain
“Two principal such proposals emerged -the first published initially in late 2010 [7] and the second published initially in early 2011 [8].”
What the sources say
- Partly supportedcites [7] Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010;126:1099–4e4. sourceExperimental — accuracy not yet measured
The Proposed Criteria section (page unavailable) sets out this paper’s proposed criteria for MCAS. The Abstract likewise says the authors will propose criteria, but neither passage establishes that two principal proposals had emerged. (LLM, conf=0.84)
- Partly supportedcites [8] Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol 2011;4:10. sourceExperimental — accuracy not yet measured
Table 2 (Introduction; page unavailable) presents proposed criteria for MCAS, and Clinical diagnostics refers to proposed revised diagnostic criteria. But the table contrasts MCAS criteria with WHO criteria for systemic mastocytosis; it does not identify two principal proposals for MCAS diagnostic criteria. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“CgA is a known product of the MC [59,60]”
What the sources say
- Could not verifycites [59] Tsuchiya S, Tachida Y, Segi-Nishida E, Okuno Y, Tamba S, Tsujimoto G, et al. Characterization of gene expression profiles for different types of mast cells pooled from mouse stomach subregions by an RNA amplification method. BMC Genomics 2009;10:35. sourceExperimental — accuracy not yet measured
The Background and Results and discussion passages describe mast-cell granule contents and products such as serine proteases and Ptgr1, but do not identify chromogranin A as a mast-cell product. Searches for “chromogranin A” and “CgA mast cell” found no passage addressing that point in our copy; page numbers were not provided. (LLM, conf=0.73)
- Could not verifycites [60] Aung G, Niyonsaba F, Ushio H, Kajiwara N, Saito H, Ikeda S, et al. Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines. Immunology 2011;132:527–39. sourceExperimental — accuracy not yet measured
Our copy of Aung et al. (2011) locates chromogranin A elsewhere: the Introduction states CgA 'is a member of the granin family found in the secretory granules of endocrine, neuroendocrine and neuronal cells', and the only cutaneous expression noted is in keratinocytes/murine skin, with catestatin occurring in normal human skin. Throughout the paper catestatin (the CgA fragment) is applied as an exogenous stimulant that makes LAD2 and peripheral-blood mast cells migrate, degranulate, mobilize Ca2+ and release LTC4/PGD2/PGE2 and cytokines (Results, Discussion) — the mast-cell mediators measured are histamine, β-hexosaminidase, eicosanoids and cytokines/chemokines, never CgA or granins. No passage in our copy states or implies that mast cells produce or store chromogranin A, and none denies it either, so this source cannot support the attributing sentence (searched: 'chromogranin A produced by mast cells', 'mast cell granules chromogranin A stored', 'catestatin stored in mast cell granules', 'granin family synthesized by mast cells'). (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“11-β-PGF 2α is the principal immediate metabolic product of both PGD 2 and PGE 2 [72][73][74].”
What the sources say
- Not checked yetcites [72] Watanabe K, Iguchi Y, Iguchi S, Arai Y, Hayaishi O, Roberts 2nd LJ. Stereospecific conversion of prostaglandin D2 to (5Z,13E)-(15S)-9 alpha-11 beta,15-trihydroxyprosta-5,13-dien-1-oic acid (9 alpha,11 beta-prostaglandin F2) and of prostaglandin H2 to prostaglandin F2 alpha by bovine lung prostaglandin F synthase. Proc Natl Acad Sci U S A 1986;83:1583–7. source
Checked before — its earlier verdict is held back until a new check runs.
- Partly supportedcites [73] Coquenlorge S, Van Landeghem L, Jaulin J, Cenac N, Vergnolle N, Duchalais E, et al. The arachidonic acid metabolite 11β-ProstaglandinF2α controls intestinal epithelial healing: deficiency in patients with Crohn’s disease. Sci Rep 2016;6:25203. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) calls 11βPGF2α the primary plasma metabolite of PGD2 and states that AKR1C3 converts PGD2 to 11βPGF2α. It does not identify 11βPGF2α as a metabolite of PGE2; its discussion of PGE2 concerns glial production and neuronal responses. (LLM, conf=0.89)
- Not checked yetcites [74] Dozier BL, Watanabe K, Duffy DM. Two pathways for prostaglandin F2 alpha synthesis by the primate periovulatory follicle. Reproduction 2008;136:53–63. source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not checked yet
29 more claims · 2 with their cited sources checked
Create a free account to see all 72 claims and to verify the 8 references still open.
- It may state two separate claims as one. 12
- Probably not a substantial claim. 30
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Such alternative approaches with less stringent criteria result in an expanding group of individuals being labeled as having MCAS, but who exhibit a wide and nearly unlimited range of symptoms claimed to be attributable to MCA without clear relation to MCs or attributes of anaphylaxis or MCA.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alternative diagnostic criteria of MCAS have also been suggested, but these alternative criteria often lack speci fi city and validation.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These criteria are much broader and less speci fi c for MCA or MCAS.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some authors have based the diagnosis of MCAS on a variety of clinical symptoms that may or may not relate to MCA. 31,34”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, MCAS patients may chronically experience certain symptoms, so that a truly asymptomatic sBT is dif fi cult to obtain. 31”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [31]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Valent et al. proposal for diagnostic criteria for MCAS
“The "20% + 2" formula for interpreting rises in tryptase, newly introduced in this proposal, as the sole acceptable (even "gold standard") laboratory parameter for diagnosing MCAS bears special attention”
§ Discussion
“though if a patient cannot be shown to have "20% + 2," then elevations in a few other relatively MC-specific mediators can be considered diagnostic.”
Citations
Cites
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey‐Goldman, R., Smolen, J. S., Wofsy, D., Boumpas, D. T., Kamen, D. L., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40930 · Cited by 2,677
IgE, mast cells, basophils, and eosinophils
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.11.017 · Cited by 1,680
Biologically active products of stimulated liver macrophages (Kupffer cells)
DECKER, K. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb19222.x · Cited by 904
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 1×
“In 2007, the first case reports were published [4, 5], followed shortly by a limited proposal for diagnostic criteria in cases where MC clonality could be identified [6].”
BackgroundValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
A global survey of changing patterns of food allergy burden in children
Prescott, S. L., Pawankar, R., Allen, K. J., Campbell, D. E., Sinn, J. K., Fiocchi, A., Ebisawa, M., Sampson, H. A., Beyer, K., & Lee, B.-W. (2013) · World Allergy Organization Journal · doi:10.1186/1939-4551-6-21 · Cited by 604
Dalstra, J., Kunst, A., Borrell, C., Breeze, E., Cambois, E., Costa, G., Geurts, J., Lahelma, E., Van Oyen, H., Rasmussen, N., et al. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyh386 · Cited by 592
Mast Cells, Mastocytosis, and Related Disorders
Theoharides, T. C., Valent, P., & Akin, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1409760 · Cited by 518 · cited 1×
“Three additional proposals [19, 23, 24] – all modest variants of the “consensus-1” criteria – have emerged, as detailed in the third through fifth entries in Supplementary Table 1.”
BackgroundThe World Incidence and Prevalence of Autoimmune Diseases is Increasing
Lerner, A., Jeremias, P., & Matthias, T. (2016) · International Journal of Celiac Disease · doi:10.12691/ijcd-3-4-8 · Cited by 508
Cited by
Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
Afrin, L. B., Weinstock, L. B., & Molderings, G. J. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.09.016 · Cited by 314
Self-citationMast cell activation symptoms are prevalent in Long-COVID
Weinstock, L. B., Brook, J. B., Walters, A. S., Goris, A., Afrin, L. B., & Molderings, G. J. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.043 · Cited by 185
Self-citationCOVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms
Malone, R. W., Tisdall, P., Fremont‐Smith, P., Liu, Y., Huang, X., White, K. M., Miorin, L., Moreno, E., Alon, A., Delaforge, E., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.633680 · Cited by 113
Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?
Voß, M., Kotrba, J., Gaffal, E., Katsoulis‐Dimitriou, K., & Dudeck, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094589 · Cited by 115
Valent, P., Hartmann, K., Bonadonna, P., Gülen, T., Brockow, K., Alvarez-Twose, I., Hermine, O., Niedoszytko, M., Carter, M. C., Hoermann, G., et al. (2022) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2022.05.007 · Cited by 90
Metadata
- Authors
- Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., McCann, K. K., McKee, D. L., Menk Otto, L., Pace, L. A., Perkins, D. D., Radovsky, L., Raleigh, M. S., Rapaport, S. A., Reinhold, E. J., Renneker, M. L., Robinson, W. A., Roland, A. M., Rosenbloom, E. S., Rowe, P. C., Ruhoy, I. S., Saperstein, D. S., Schlosser, D. A., Schofield, J. R., Settle, J. E., Weinstock, L. B., Wengenroth, M., Westaway, M., Xi, S. C., & Molderings, G. J.
- Affiliations
- Armonk Integrative Medicine , Purchase, NY , USA
- My Passion 4 Health , Tucson , AZ , USA
- Medical College of Wisconsin (US)
- Plaza Infectious Disease , Kansas City , MO , USA
- Alaska Internal Medicine and Pediatrics , Anchorage , AK , USA
- Peachtree Allergy and Asthma , Atlanta , GA , USA
- Beaver Medical Group (US)
- University of Kentucky (US)
- Complex Cares, LLC , Shoreview , MN , USA
- Allergy and Asthma Specialists of Cadillac , Cadillac , MI , USA
- Oregon Health & Science University (US)
- Healing Dragon, Portland , OR , USA
- Hoffman Centre for Integrative and Functional Medicine , Calgary , Alberta , Canada
- Center for Complex Diseases , Mountain View , CA , USA
- CHI Health (US)
- Healthwell Physical Therapy Group , San Francisco , CA , USA
- Heart of the Valley Pediatric Cardiology , Pleasanton , CA , USA
- The Spring Center , Costa Mesa , CA , USA
- Integrative Cancer Consulting, Aptos , CA , USA
- Helfgott Research Institute , National College of Natural Medicine , Portland , OR , USA
- University of Utah (US)
- Elevate Health , Portland , OR , USA
- St. Paul , MN , USA
- Restoration Healthcare , Irvine , CA , USA
- Haven Medical , Chapel Hill , NC , USA
- Royal College of General Practitioners (GB)
- University of California, San Francisco (US)
- University of Colorado Denver (US)
- Sacramento , CA , USA
- Johns Hopkins University (US)
- Center for Healing Neurology , Seattle , WA , USA
- Center for Complex Neurology, EDS and POTS , Phoenix , AZ , USA
- Patient Navigator, LLC , Reston , VA , USA
- University of Colorado Anschutz (US)
- Washington University in St. Louis (US)
- University of Lübeck (DE)
- Westaway Medical , Brisbane , Queensland , Australia
- University of Southern California (US)
- University Hospital Bonn (DE)
- Corresponding author
- Afrin, Lawrence B.
- ORCID
- Venue
- Diagnosis
- Publisher
- Walter de Gruyter GmbH
- Published
- 2020-04-22
- Volume
- 8
- Issue
- 2
- Pages
- 137-152
- ISSN
- 2194-8011 (ISSN-L)
- 2194-802X
- OpenAlex
- W3020152139
- Cited by
- 115
- References
- 97
- Citations by year
- 2026: 19 · 2025: 13 · 2024: 15 · 2023: 21 · 2022: 24 · 2021: 17 · 2020: 5
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diagnosis (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD085852)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- mast cell activation syndrome, diagnostic criteria, mast cell activation, overdiagnosis, underdiagnosis, mastocytosis
- MeSH terms
- Consensus Statements as Topic, Humans, Mast Cells, Mastocytosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis of mast cell activation syndrome: a global "consensus-2". https://app.cochat.ai/papers/10.1515/dx-2020-0005
- The paper
- Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., . . . Molderings, G. J. (2021). Diagnosis of mast cell activation syndrome: a global "consensus-2". Diagnosis. https://doi.org/10.1515/dx-2020-0005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.